The effect of salicylates on insulin sensitivity

Insulin resistance, a characteristic feature of type 2 diabetes, is associated with central obesity, hypertension, dyslipidemia, and cardiovascular disease (and death) (1). The mechanism of insulin resistance is complex and largely unknown. Both in animals and in humans, however, insulin resistance can be induced by lipid infusion. In a recent issue of the JCI, Kim and colleagues presented new data on the mechanisms responsible for the induction of insulin resistance by lipids. In an elegant set of experiments, they show that activation of IKK-β is important in fat-induced insulin (2). High-dose salicylate prevents the fat-induced defects in insulin signaling. Based on these findings, the authors suggest that “salicylates represent a potentially novel class of therapeutic agents for type 2 diabetes” (2).

Although the carefully performed study by Kim et al. provides new insight into the mechanisms of fat-induced insulin resistance, we would like to caution against the preliminary conclusion concerning beneficial effects of salicylates on insulin resistance. First of all, in contrast to the findings of Kim et al. in the triglyceride (TG) infusion model in the rat, earlier studies in human volunteers using hyperglycemic clamp techniques reported increased insulin resistance by salicylate compounds (3, 4). These findings suggest that the effects of salicylates may depend on the experimental model, and possibly on the species studied.

There are also strong theoretical arguments that salicylates have deleterious effects on insulin resistance. Similar to TGs (or fatty acids), the proinflammatory cytokine TNF-α synthesized by adipocytes is a central factor in the pathogenesis of insulin resistance (5). As underlined also by Kim et al., there is significant overlap between the intracellular events induced by fatty acids and TNF in insulin-sensitive tissues: both activate IKK-β and decrease IRS-1 tyrosine phosphorylation, and both increase intracellular ceramide concentrations, which leads to inhibition of Akt/protein kinase B activation and impaired GLUT-4 translocation (these relationships are outlined in Figure 1) (6–8).

The effects of salicylates on TNF-induced insulin resistance are completely opposite to those reported by Kim and colleagues on fat-induced insulin resistance. TNF induces the synthesis of prostaglandins (PGs), which function as a negative feedback mechanism by inhibiting the upstream TNF production (9). We and others have shown in healthy volunteers that administration of aspirin or indomethacin, both strong inhibitors of PG synthesis, enhances TNF production capacity at least twofold (10, 11), which can negatively affect insulin sensitivity. In addition, PGs stimulate synthesis of leptin, an adipocytokine known to decrease insulin resistance through improvement of IRS-1-associated phosphatidylinositol (PI) 3-kinase activity (12, 13). Although not yet experimentally tested, inhibition of PG synthesis by salicylate compounds may also negatively influence insulin sensitivity by inhibition of leptin release. Thus, aspirin could increase insulin resistance through at least two mechanisms mediated by the inhibition of PG synthesis, namely the upregulation of TNF synthesis and the inhibition of leptin release (Figure 1). There are other important endogenous factors modulating the resistance to insulin: adiponectin reverses insulin resistance, possibly in part by inhibition of TNF synthesis, whereas resistin impairs glucose tolerance and insulin action (12, 14). The influence of salicylates on the modulation of these proteins is not known.

In conclusion, the influence of salicylate compounds on insulin sensitivity is multifactorial and involves both beneficial and deleterious effects. This should not preclude patients from taking low-dose aspirin to prevent cardiovascular disease (15), but more basal and clinical studies are needed.
are needed before recommending higher dosages of salicylates for the treatment of type 2 diabetes itself.

Mihai G. Netea,1 Cees J. Tack,1 Paetrick M. Netten,2 Jos A. Lutterman,1 and Jos W.M. Van der Meer1

1Department of Medicine, University Medical Center St. Radboud, Nijmegen, The Netherlands
2Department of Internal Medicine, Bosch Medischcentrum, ‘s-Hertogenbosch, The Netherlands

Address correspondence to: Mihai G. Netea, Department of Medicine (541), University Medical Center St. Radboud, Geert Grooteplein 8, PO Box 9101, 6500 HB Nijmegen, The Netherlands.

Phone: 31-24-3614652; Fax: 31-24-3541734; E-mail: M.Netea@aig.azn.nl.


Kim et al. reply — We would like to thank Netea et al. for their thoughtful comments regarding our article (1). First of all, we would like to emphasize that we are not advocating the use of high-dose aspirin for the treatment of type 2 diabetes. In fact, we strongly recommend against it in view of aspirin’s potential long-term toxicities at high doses. Our studies used high-dose aspirin as a pharmacological tool to identify IKK-β as a potentially novel therapeutic target for type 2 diabetes. This hypothesis, developed by Yuan et al. (2), led to our finding that Ikk−β−/− mice were protected from obesity- and diet-induced insulin resistance (2) as well as following 5-hour lipid infusion (1). Because aspirin is a weak inhibitor of IKK-β, high doses of the drug restore insulin sensitivity in each of these models of insulin resistance.

We are aware of the previous studies that have shown that aspirin therapy actually causes insulin resistance (3–5). We believe the major reason for the discrepancy is not due to species differences as suggested by Netea et al. but rather the lower dose and duration of salicylate therapy used in these human studies. Even older clinical trials clearly showed hypoglycemic effects of high doses (4–10 g/day) of aspirin and salicylate that occur progressively over 1 to 2 or 3 weeks (6). Using corresponding therapeutic regimens, we saw beneficial effects in rodents (1, 2) and, in more recent studies by our group, in humans (7). High-dose salicylate treatment (about 7 g/day for 2 weeks) was very successful in lowering fasting and postprandial hyperglycemia in patients with type 2 diabetes, which could partly be attributed to increased peripheral insulin sensitivity as assessed by a hyperinsulinemic-euglycemic clamp (7).

In summary, we believe that our data (1) support the hypothesis that fat induces insulin resistance through activation of a serine/threonine kinase cascade leading to decreased IRS-1/IRS-2-associated phosphatidylinositol 3-kinase activity in muscle and liver (2, 8), and that IKK-β, and the steps leading to its activation, are potential novel therapeutic targets for type 2 diabetes mellitus.

Jason K. Kim, Steven E. Shoelson, and Gerald I. Shulman